{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:03:54Z","timestamp":1773093834348,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"DOI":"10.7759\/cureus.104900","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:05:17Z","timestamp":1773057917000},"source":"Crossref","is-referenced-by-count":0,"title":["Refractory Clostridioides difficile Colitis in a Patient With Hidradenitis Suppurativa: Consequences of Long-Term Clindamycin and Multi-agent Anti-TNF Therapy"],"prefix":"10.7759","author":[{"given":"Cameron I","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew K","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alande","family":"Brezault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03539-6","article-title":"Clostridium difficile infection: review","volume":"38","author":"Czepiel J","year":"2019","unstructured":"Czepiel J, Dr\u00f3\u017cd\u017c M, Pituch H, et al.. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019, 38:1211-21. 10.1007\/s10096-019-03539-6","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae274","article-title":"The clinical effectiveness of fidaxomicin compared to vancomycin in the treatment of Clostridioides difficile infection, a single-center real-world experience","volume":"230","author":"Alsoubani M","year":"2024","unstructured":"Alsoubani M, Chow JK, Rodday AM, McDermott LA, Walk ST, Kent DM, Snydman DR. The clinical effectiveness of fidaxomicin compared to vancomycin in the treatment of Clostridioides difficile infection, a single-center real-world experience. J Infect Dis. 2024, 230:1501-9. 10.1093\/infdis\/jiae274","journal-title":"J Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger JG","year":"2024","unstructured":"Krueger JG, Frew J, Jemec GB, et al.. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol. 2024, 190:149-62. 10.1093\/bjd\/ljad345","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21709","article-title":"Clostridium difficile infection risk in patients with hidradenitis suppurativa","volume":"187","author":"Sanghvi AP","year":"2022","unstructured":"Sanghvi AP, Miles JA, Sayed C. Clostridium difficile infection risk in patients with hidradenitis suppurativa. Br J Dermatol. 2022, 187:800-2. 10.1111\/bjd.21709","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.30739","article-title":"Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA adverse event reporting system","volume":"16","author":"Teng C","year":"2019","unstructured":"Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA adverse event reporting system. Int J Med Sci. 2019, 16:630-5. 10.7150\/ijms.30739","journal-title":"Int J Med Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2020.03.002","article-title":"Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease","volume":"68","author":"Gholam-Mostafaei FS","year":"2020","unstructured":"Gholam-Mostafaei FS, Yadegar A, Aghdaei HA, Azimirad M, Daryani NE, Zali MR. Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease. Curr Res Transl Med. 2020, 68:125-30. 10.1016\/j.retram.2020.03.002","journal-title":"Curr Res Transl Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.10.008","article-title":"The effect of antibiotics on the composition of the intestinal microbiota - a systematic review","volume":"79","author":"Zimmermann P","year":"2019","unstructured":"Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota - a systematic review. J Infect. 2019, 79:471-89. 10.1016\/j.jinf.2019.10.008","journal-title":"J Infect"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000002047","article-title":"The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of Clostridioides difficile infection","volume":"64","author":"Poylin V","year":"2021","unstructured":"Poylin V, Hawkins AT, Bhama AR, et al.. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of Clostridioides difficile infection. Dis Colon Rectum. 2021, 64:650-68. 10.1097\/DCR.0000000000002047","journal-title":"Dis Colon Rectum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab233","article-title":"A tapered-pulsed fidaxomicin regimen following treatment in patients with multiple Clostridioides difficile infection recurrences","volume":"73","author":"Skinner AM","year":"2021","unstructured":"Skinner AM, Tan X, Sirbu BD, Danziger LH, Gerding DN, Johnson S. A tapered-pulsed fidaxomicin regimen following treatment in patients with multiple Clostridioides difficile infection recurrences. Clin Infect Dis. 2021, 73:1107-9. 10.1093\/cid\/ciab233","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery B","year":"2018","unstructured":"Guery B, Menichetti F, Anttila VJ, et al.. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial. Lancet Infect Dis. 2018, 18:296-307. 10.1016\/S1473-3099(17)30751-X","journal-title":"Lancet Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020958","article-title":"Pro-inflammatory cytokines enhanced in vitro cytotoxic activity of Clostridioides difficile toxin B in enteric glial cells: the Achilles heel of Clostridioides difficile infection?","volume":"25","author":"Fettucciari K","year":"2024","unstructured":"Fettucciari K, Spaterna A, Marconi P, Bassotti G. Pro-inflammatory cytokines enhanced in vitro cytotoxic activity of Clostridioides difficile toxin B in enteric glial cells: the Achilles heel of Clostridioides difficile infection?. Int J Mol Sci. 2024, 25:10.3390\/ijms25020958","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy845","article-title":"Clostridium difficile in immunocompromised hosts: a review of epidemiology, risk factors, treatment, and prevention","volume":"68","author":"Revolinski SL","year":"2019","unstructured":"Revolinski SL, Munoz-Price LS. Clostridium difficile in immunocompromised hosts: a review of epidemiology, risk factors, treatment, and prevention. Clin Infect Dis. 2019, 68:2144-53. 10.1093\/cid\/ciy845","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081833","article-title":"Unravelling the link between hidradenitis suppurativa and inflammatory bowel disease: a literature review","volume":"13","author":"Mpakogiannis K","year":"2025","unstructured":"Mpakogiannis K, Fousekis FS, Karampinis E, Mastoridou E, Gaitanis G, Katsanos KH. Unravelling the link between hidradenitis suppurativa and inflammatory bowel disease: a literature review. Biomedicines. 2025, 13:10.3390\/biomedicines13081833","journal-title":"Biomedicines"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1042\/CS20171107","article-title":"Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins","volume":"132","author":"Lau WL","year":"2018","unstructured":"Lau WL, Savoj J, Nakata MB, Vaziri ND. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. Clin Sci (Lond). 2018, 132:509-22. 10.1042\/CS20171107","journal-title":"Clin Sci (Lond)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2020-216029","article-title":"Type 2 diabetes mellitus and antibiotic-resistant infections: a systematic review and meta-analysis","volume":"76","author":"Carrillo-Larco RM","year":"2022","unstructured":"Carrillo-Larco RM, Anza-Ram\u00edrez C, Saal-Zapata G, Villarreal-Zegarra D, Zafra-Tanaka JH, Ugarte-Gil C, Bernab\u00e9-Ortiz A. Type 2 diabetes mellitus and antibiotic-resistant infections: a systematic review and meta-analysis. J Epidemiol Community Health. 2022, 76:75-84. 10.1136\/jech-2020-216029","journal-title":"J Epidemiol Community Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad606","article-title":"An open-label, randomized trial comparing fidaxomicin with oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients receiving concomitant antibiotics for concurrent infections","volume":"78","author":"Rao K","year":"2024","unstructured":"Rao K, Zhao Q, Bell J, et al.. An open-label, randomized trial comparing fidaxomicin with oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients receiving concomitant antibiotics for concurrent infections. Clin Infect Dis. 2024, 78:277-82. 10.1093\/cid\/ciad606","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2734","article-title":"Path of least recurrence: a systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection","volume":"42","author":"Liao JX","year":"2022","unstructured":"Liao JX, Appaneal HJ, Vicent ML, Vyas A, LaPlante KL. Path of least recurrence: a systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection. Pharmacotherapy. 2022, 42:810-27. 10.1002\/phar.2734","journal-title":"Pharmacotherapy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2024.03.024","article-title":"Management of Clostridioides difficile infection: diagnosis, treatment, and future perspectives","volume":"137","author":"Cymbal M","year":"2024","unstructured":"Cymbal M, Chatterjee A, Baggott B, Auron M. Management of Clostridioides difficile infection: diagnosis, treatment, and future perspectives. Am J Med. 2024, 137:571-6. 10.1016\/j.amjmed.2024.03.024","journal-title":"Am J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/459996-refractory-clostridioides-difficile-colitis-in-a-patient-with-hidradenitis-suppurativa-consequences-of-long-term-clindamycin-and-multi-agent-anti-tnf-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:05:17Z","timestamp":1773057917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/459996-refractory-clostridioides-difficile-colitis-in-a-patient-with-hidradenitis-suppurativa-consequences-of-long-term-clindamycin-and-multi-agent-anti-tnf-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.104900","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}